COX-2 inhibitors and heart.
Manoria
Pankaj
P
Department of Cardiology, Bhopal Memorial Hospital and Resarch Centre, and Gandhi Medical College, Bhopal. pankajmanoria@rediffmail.com
Manoria
P C
PC
D002319:Cardiovascular System / Q000187:drug effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000453:epidemiology; D015994:Incidence; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D018570:Risk Assessment; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate; D000096926:Benzenesulfonamides
D052246:Cyclooxygenase 2 Inhibitors; D007555:Isoxazoles; D007783:Lactones; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides